Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2022-10-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of BJ-001, a human IL-15
fusion protein, administered via subcutaneous injections, as a single agent and in
combination with PD-1 or PD-L1 Inhibitor in adult patients with Locally Advanced/Metastatic
Solid Tumors